🇺🇸 FDA
Patent

US 10233452

Compositions and methods for increasing erythropoietin (EPO) production

granted A61KA61K31/713

Quick answer

US patent 10233452 (Compositions and methods for increasing erythropoietin (EPO) production) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/713